Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business. The health care giant said Tuesday that it will separate its orthopedics business into ...

The combination measles, mumps and rubella vaccine — better known as the MMR shot —should be split into three separate vaccines, US Centers for Disease Control and Prevention Acting Director Jim ...

Acting CDC Director Jim O'Neill is calling for the measles, mumps and rubella vaccine to be split into three separate shots. It comes as the CDC approves new guidelines for updated COVID vaccines. Dr.

Stock-split euphoria has played a role in sending the benchmark S&P 500 to new heights. An industry titan with macro tailwinds and an enviable share repurchase program is ripe for the picking by ...

INDIANAPOLIS — Corteva Agriscience, a farm technology company based in Indianapolis, is splitting into two separate entities. Corteva’s planned split is expected to be finalized in the second half of ...

Corteva CTVA1.76%increase; green up pointing triangle supplies farmers with chemicals to kill weeds and pests as well as the biotech seeds designed to withstand them. On Wednesday the company said ...

Oct 1 (Reuters) - Corteva (CTVA.N), opens new tab said on Wednesday it would separate its seed and pesticide businesses into separate listed companies, as the agrichemicals firm seeks to sharpen its ...

Corteva will separate into two publicly traded companies: New Corteva (crop protection) and SpinCo (seed business). The spin-off is expected to be completed in the second half of 2026 as a tax-free ...

(Reuters) -Corteva said on Wednesday it would separate its seed and pesticide businesses into separate listed companies, as the agrichemicals firm seeks to sharpen its strategic focus. The separation ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies. Referred to as “Royalty Management Co” and ...

AnaptysBio plans to split into two publicly traded companies, with one entity taking forward the biopharma’s clinical-stage pipeline and the other overseeing its royalty-based agreements. The crown ...